Home ›
Breast Cancer Trials ›
NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Trial Details
NCT ID NCT05900895
Phase PHASE1
Sponsor Mary D Chamberlin
Status RECRUITING
Cancer Type Breast Cancer
Interventions
Locations (sample) Lebanon, New Hampshire, United States|43.64229,-72.25176
Key Eligibility Criteria
Post-menopausal women with ER+/HER2- breast cancer. Metastatic or locoregional recurrence not amenable to treatment with curative intent. Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →